Market Momentum: Chemours Company (CC) Registers a 3.78% Increase, Closing at $15.66

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

Chemours Company (NYSE: CC) closed the day trading at $15.66 up 3.78% from the previous closing price of $15.09. In other words, the price has increased by $3.78 from its previous closing price. On the day, 4.31 million shares were traded. CC stock price reached its highest trading level at $16.39 during the session, while it also had its lowest trading level at $15.21.

Ratios:

For a better understanding of CC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.83 and its Current Ratio is at 1.68. In the meantime, Its Debt-to-Equity ratio is 18.59 whereas as Long-Term Debt/Eq ratio is at 18.18.

On January 28, 2025, Truist started tracking the stock assigning a Buy rating and target price of $27. UBS Upgraded its Neutral to Buy on July 09, 2024, whereas the target price for the stock was revised from $28 to $30.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 08 ’25 when Dignam Denise bought 4,068 shares for $12.06 per share. The transaction valued at 49,060 led to the insider holds 191,546 shares of the business.

Gumpel Damian bought 13,400 shares of CC for $123,548 on Jun 02 ’25. The insider now owns 123,879 shares after completing the transaction at $9.22 per share. On Jun 03 ’25, another insider, Gumpel Damian, who serves as the insider of the company, bought 7,822 shares for $9.95 each. As a result, the insider paid 77,828 and bolstered with 131,701 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CC now has a Market Capitalization of 2344270592 and an Enterprise Value of 6255275520. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.40 while its Price-to-Book (P/B) ratio in mrq is 9.89. Its current Enterprise Value per Revenue stands at 1.069 whereas that against EBITDA is 9.421.

Stock Price History:

The Beta on a monthly basis for CC is 1.64, which has changed by -0.084210515 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, CC has reached a high of $22.38, while it has fallen to a 52-week low of $9.13. The 50-Day Moving Average of the stock is 14.79%, while the 200-Day Moving Average is calculated to be 6.23%.

Shares Statistics:

Over the past 3-months, CC traded about 4.27M shares per day on average, while over the past 10 days, CC traded about 2913620 shares per day. A total of 149.70M shares are outstanding, with a floating share count of 148.58M. Insiders hold about 0.75% of the company’s shares, while institutions hold 100.63% stake in the company. Shares short for CC as of 1755216000 were 18177978 with a Short Ratio of 4.25, compared to 1752537600 on 16003045. Therefore, it implies a Short% of Shares Outstanding of 18177978 and a Short% of Float of 17.849999999999998.

Dividends & Splits

CC’s forward annual dividend rate is 0.68, up from 0.838 a year ago. Against a Trailing Annual Dividend Yield of 0.055533465The stock’s 5-year Average Dividend Yield is 4.07.

Earnings Estimates

The stock of Chemours Company (CC) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.25, with high estimates of $0.31 and low estimates of $0.18.

Analysts are recommending an EPS of between $1.5 and $1.12 for the fiscal current year, implying an average EPS of $1.23. EPS for the following year is $2.12, with 9.0 analysts recommending between $2.61 and $1.46.

Revenue Estimates

7 analysts predict $1.5B in revenue for the current quarter. It ranges from a high estimate of $1.53B to a low estimate of $1.42B. As of the current estimate, Chemours Company’s year-ago sales were $1.5BFor the next quarter, 7 analysts are estimating revenue of $1.41B. There is a high estimate of $1.43B for the next quarter, whereas the lowest estimate is $1.39B.

A total of 9 analysts have provided revenue estimates for CC’s current fiscal year. The highest revenue estimate was $5.95B, while the lowest revenue estimate was $5.8B, resulting in an average revenue estimate of $5.9B. In the same quarter a year ago, actual revenue was $5.78BBased on 9 analysts’ estimates, the company’s revenue will be $6.17B in the next fiscal year. The high estimate is $6.27B and the low estimate is $6.06B.

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.